> ## Content Index > Fetch the complete content index at: https://www.bullished.co/llms.txt > Use this file to discover other available public pages before exploring further. # Beta Bionics Cuts Its Mint Deferral Fear: Fewer Customers Are Waiting Than Feared - URL: https://www.bullished.co/beta-bionics-cuts-its-mint-deferral-fear-fewer-customers-are-waiting-than-feared-297d9d31/ - Published: 2026-10-28T06:36:09.000Z - Updated: 2026-10-28T06:36:09.000Z - Description: Management narrowed 2026 revenue guidance to $124 million to $126 million and said it expects to more than recover delayed sales in 2027. - Author: Matteo Parrino - Tags: Earnings, BBNX, Industry: Healthcare Fewer customers than feared are holding off on [Beta Bionics](https://www.bullished.co/tag/bbnx/)' current iLet pump to wait for its new Mint patch pump, CEO Sean Saint said on the company's third-quarter earnings call Tuesday. The company raised the low end of its 2026 revenue outlook to [$124 million to $126 million](https://seekingalpha.com/news/4658563-beta-bionics-expects-124m-126m-2026-revenue-and-targets-mint-launch-in-q1-2027?ref=bullished.co), from $121 million to $126 million. ## Deferrals arrive slower than planned Beta Bionics, which makes the iLet Bionic Pancreas insulin pump system, had built a potential fourth-quarter revenue deferral of up to $10 million into earlier guidance, CFO Stephen Feider said, because new users might wait for Mint. Some evidence of that is showing, he said, but not at the rate management first expected when Mint won FDA clearance in September. The new outlook implies $29 million to $31 million of fourth-quarter revenue. Third-quarter net sales hit a [record $35.5 million](https://www.globenewswire.com/de/news-release/2026/10/27/3389593/0/en/beta-bionics-announces-third-quarter-2026-financial-results-and-updates-full-year-2026-guidance.html?ref=bullished.co), up about 30% from a year earlier, and gross margin was 57.3%. A Wells Fargo analyst put the deferral being recovered next year at $8.5 million. Feider replied that the math was accurate and that the company expects to more than make up any deferral in 2027. ## Why customers aren't waiting Saint put it down to awareness. Market research on Mint left management "very surprised and at some level scared" because users loved the product, he said, so the company was conservative on deferrals. But most people are not "wandering through their lives wondering when mint is coming out," and their doctors are not yet pushing it. Feider cited an internal survey of a little over 300 current users: almost 90% said they would switch to Mint if their monthly out-of-pocket cost did not change. He called it a relatively small sample. ## Coverage and economics at launch The company expects to launch Mint fully in the United States in the first quarter of 2027\. Feider said roughly 40% of covered lives should have coverage at launch, rising to around 50% by the end of 2027. Mint's reimbursement should run about six times the roughly $70 a month the company earns per patient on iLet supplies sold through durable medical equipment channels. Feider said Mint's gross margin will be dilutive in 2027. The company had about $374 million in cash and investments as of September 30, 2026, after a September public offering that raised about $161 million in net proceeds. ## 3D Intelligence setback Saint also said the company withdrew its FDA submission for its 3D Intelligence algorithm and plans to resubmit in mid-fourth quarter, with a launch around mid-2027 expected, subject to clearance. He said the FDA's questions concerned validation of the company's simulator, not the algorithm, and an earlier clearance this year remains possible. Feider said new patient starts in the fourth quarter should fall about 20% from the third quarter. ### Sources - [Beta Bionics expects $124M-$126M 2026 revenue and targets Mint launch in Q1 2027 (NASDAQ:BBNX) | Seeking Alpha](https://seekingalpha.com/news/4658563-beta-bionics-expects-124m-126m-2026-revenue-and-targets-mint-launch-in-q1-2027?ref=bullished.co) — seekingalpha.com - [Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates](https://finance.yahoo.com/healthcare/articles/beta-bionics-inc-bbnx-reports-201502912.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance - [Beta Bionics GAAP EPS of -$0.52 in-line, revenue of $35.5M beats by $0.91M (BBNX:NASDAQ)](https://seekingalpha.com/news/4658347-beta-bionics-gaap-eps-of-0%5F52-in-line-revenue-of-35%5F5m-beats-by-0%5F91m?ref=bullished.co) — seekingalpha.com - [Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026 – Company Announcement - FT.com](https://markets-data-api-proxy.ft.com/data/announce/full?dockey=1330-9835369en-7H2PAEA1RDM6SG5OFD393UGTEJ&ref=bullished.co) — Financial Times - [Beta Bionics Announces Third Quarter 2026 Financial Results](https://www.globenewswire.com/de/news-release/2026/10/27/3389593/0/en/beta-bionics-announces-third-quarter-2026-financial-results-and-updates-full-year-2026-guidance.html?ref=bullished.co) — globenewswire.com ### More on Beta Bionics - [Beta Bionics Drops Its 2028 Cash-Runway Date After $161.3 Million Stock Sale](https://www.bullished.co/beta-bionics-drops-its-2028-cash-runway-date-after-161-3-million-stock-sale-c19e7c1f/) - [Beta Bionics Pulls Its 3D Intelligence FDA Filing And Warns Mint Could Defer Up To $8.5 Million](https://www.bullished.co/beta-bionics-pulls-its-3d-intelligence-fda-filing-and-warns-mint-could-defer-up-to-8-5-98706cee/) - [T. Rowe Price Reports 16.6% Passive Stake In Beta Bionics, 13G Shows](https://www.bullished.co/t-rowe-price-reports-16-6-passive-stake-in-beta-bionics-13g-shows-c2c87b46/) [All Beta Bionics (BBNX) coverage →](https://www.bullished.co/tag/bbnx/)